drugset / Trial / NCT02519777
Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
People infected with HIV often have cognitive dysfunction even if they are on antiretroviral therapy (ART) and have undetectable viral loads. The study evaluated if the addition of maraviroc (MVC) and dolutegravir (DTG) (which are two antiretroviral \[ARV\] medications) to participants' existing ART regimens improved participants' neurocognitive performance.
Timeline
- Start
- 2016-04-21
- Primary completion
- 2019-12-02
- Completion
- 2021-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dolutegravir | Other / unclassified | 50 mg | Oral |
| Subject | Maraviroc | Other / unclassified | 150 mg | Oral |
| Subject | Maraviroc | Other / unclassified | 300 mg | Oral |
| Subject | Maraviroc | Other / unclassified | 600 mg | Oral |